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Abstract
Background: Lipoprotein(a) (Lp(a)) excess is an independent risk factor of coronary artery disease (CAD) and
have shown wide ethnic variations. Further, lipid parameters used in the assessment and management of risk
factors for CAD may not reflect accurately the disease or severity if the patients are on pharmacological
interventions when compared to Lp(a). Lp(a) levels of Sri Lankan CAD patients awaiting coronary artery
bypass graft are not documented.
Methods: A cross sectional study was carried out with patients (n = 102) awaiting coronary artery bypass graft
at a tertiary healthcare institution in Sri Lanka. Lp(a) was determined by immunoturbidimetric method
(Konelab 20XT) and information on risk factors collected using a standardized questionnaire. The severity of
CAD was determined by Gensini score. Lipid parameters and pharmacological treatment data were obtained
from the Medical Records. Data were analysed using independent sample t-test, Pearson and Spearman tests
respectively.
Results: Total cholesterol (TC), LDL cholesterol (LDLc) and HDL cholesterol (HDLc) of the total study sample
(average ± SD) were, 150 ± 36 mg/dL, 92 ± 36 mg/dL and 34 ± 9 mg/dL respectively with no significant difference
irrespective of being on pharmacological treatment or not. All lipid parameters were significantly high (p < 0.05) in
females. The average Lp(a) was 50 ± 38 (SD) mg/dL with no significant difference in males or females independent of
being on treatment (50 ± 39 mg/dL) or not (49 ± 39 mg/dL) and above the cut off value (30 mg/dL).
Conclusions: Despite pharmacological interventions 27 % of the study population had high LDLc and majority low
HDLc. Mean Lp(a) was in excess irrespective of risk factors or being on treatment or not and is confirmed as an
independent, potential marker for assessing the susceptibility for CAD especially in those with other intermediate risk
factors but considered non-hyperlipidemic by conventional methods.
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Background
Cardio Vascular Disease (CVD) is a leading cause of
death in the world. In Sri Lanka 40 % of proportional
mortality is due to CVD [1]. South Asians are suscep-
tible to Acute Myocardial Infarction (AMI) at an earlier
age as they tend to develop higher risk-factor levels
much earlier in life [2]. Sudden cardiac death (SCD) is
estimated to account for 50 % of deaths from cardiovas-
cular causes and about half of these deaths occur in sub-
jects who were previously undiagnosed with heart
disease [3, 4]. Coronary artery disease is the underlying
cause in 80 % of SCDs, consequently, risk factors for
coronary artery disease also predispose to SCD [3]. Risk
factors for CVD comprise dyslipidemia, diabetes, hyperten-
sion, obesity, sedentary lifestyle, smoking, alcohol, family
history, menopause and advancing age [1]. Further, homo-
cysteine, fibrinogen, lipoprotein(a), low density lipoprotein
particle size and c-reactive protein are the conditional risk
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factors that contribute to CVD [1]. Recently it has been
shown that factors associated with culprit plaque rupture
(CPR) to be different depending on clinical presentation.
Hypertension was the only clinical predictor for STEMI,
while advanced age, diabetes mellitus and hyperlipidaemia
were the predictors in NSTEMI and unstable angina with
no clinical predictor for stable angina [5].
The prevalence of hypercholesterolemia, hypertriglyc-
eridemia and low HDLc were 14.86, 8.46 and 11.18 %
among Sri Lankan adults [6]. A subsequent study reported
elevated triglyceride (TG) and low HDLc in 12.2 % of sub-
jects of <16 years and 24.5 % of subjects >16 years with a
high prevalence in males [7]. A more recent study indicate
an increasing trend in risk factors for CAD among Sri
Lankans with the prevalence of hypercholesterolemia
(>5.2 mmol/l), high LDLc (>3.4 mmol/L), high TG
(>1.7 mmol/L) and low HDLc (<1.0 mmol/L) being 53.6,
24.7, 22.7 and 53.1 % respectively [8]. Statins are the
most effective drug therapy used in controlling LDL
cholesterol levels.
Management of lipid levels as part of risk factor modifica-
tion associated with CAD is usually based on lipid profiles.
Several studies indicate elevated Lp(a) is independently and
linearly predictive of future adverse coronary events [9, 10].
Lp(a) excess increase the risk of premature CAD 3–100
fold depending on the absence or presence of concomitant
risk factors [11, 12]. The inter-individual variability in the
concentration of Lp (a) is mainly due to genetic regulation
of rate of apoprotein (a) production [13]. Lp(a) promote
pro-atherogenic processes by many mechanisms ie; inter-
acting with fibrin and tissue matrix components in vessel
walls [14, 15], inhibiting activation of plasminogen to plas-
min [16], inhibiting plasmin mediated activation of trans-
forming growth factor β (TGF-β) leading to increased
proliferation of smooth muscle cells [17] and promoting in-
flammatory process by inducing monocyte chemotactic ac-
tivity of vascular endothelial cells [18]. Thus Lp(a) would be
a better risk marker for management of those with CAD
and also for prediction of CAD susceptibility.
Patients with chronic stable angina undergoing diagnostic
coronary angiography had significantly high (p = 0.002)
plasma Lp(a) concentration than those without CAD. A
significantly higher Lp(a) concentrations in CAD patients
with a history of myocardial infarction (MI) (52.5 mg/dL)
was observed compared to patients without MI
(25.2 mg/dL) [19]. A South Indian study confirms the
positive correlation with Lp(a) and severity of CHD
[12]. As Lp(a) levels have shown wide ethnic varia-
tions [20] the present study assessed Lp(a) and lipid
profile parameters of patients with confirmed diagno-
sis of CAD to observe the association of Lp(a) levels
and lipid parameters and to study the effect of lipid
lowering drugs on these parameters in a Sri Lankan
study sample as these data are currently unavailable.
Methods
Study design and sample calculation
The current research was conducted as a prospective
cross sectional study during the years 2013 and 2014.
Study sample consisted of consenting patients (n = 102)
awaiting Coronary Artery Bypass Graft (CABG) at the
Cardiothoracic Unit, Sri Jayewardenepura General
Hospital, Sri Lanka. The required sample size with an
estimated prevalence of 30 % CVD [21], at 95 %
significance level and a 10 % margin of error was 81.
Since some diagnosed as CVD may not be CAD a
study sample of 102 was enrolled.
Lipoprotein(a) assay
Pre-operative blood samples were collected in to plain
tubes. Serum was separated (3500 rpm, 5–10 min) and
Lp(a) content was measured by immunoturbidimetric
method (Thermo Scientific, Finland). Lipoprotein(a)
calibrator and control (Thermo Scientific, Finland) were
used for calibration. A specific anti serum (5 μL of anti-
human Lp(a) from rabbit, NaN3 and NaCl) was added to
buffered (140 μL; phosphate buffer saline) serum
(24 μL), mixed and incubated at 37 °C. The absorbance
of the immune-complex, produced from Lp(a) and anti-
serum was measured at 340 nm (Konelab 20XT). The
absorbance was considered proportional to the concen-
tration of Lp(a).
Lipid profile, risk factor data and severity of CAD
Data on total cholesterol (TC), low density lipoprotein
cholesterol (LDLc), high density lipoprotein cholesterol
(HDLc), triglyceride (TG) were collected from each
patient’s data records and TC:HDLc ratio calculated. A
standardized interviewer administered questionnaire was
used to collect data on risk factors related to develop-
ment of CAD. The Gensini score system was used to
evaluate the severity of CAD from coronary angiography
[22]. The data on coronary angiography were gathered
from the medical records. The Gensini score was
computed by assigning a severity score according to the
degree of luminal narrowing and geographical importance
of each coronary stenosis. The sum severity score of all
coronary arteries was expressed as the Gensini score.
Statistical analysis
The data are presented as mean ± 1 standard deviation
(SD). P value of less than 0.05 (p < 0.05) was considered
to be significant. Independent sample t-test and paired
sample t-test were used for analysis of parametric
variables. Correlations of parametric data were analysed
by Spearman test.
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Results
Demographic data and risk factors of the study sample
are included in Table 1. The study sample comprised of
102 patients awaiting Coronary Artery Bypass Graft
(CABG) at Sri Jayewardenepura General Hospital, Sri
Lanka. Males constituted 65.7 % (n = 67) of the sample.
Majority of the patients (43.1 %) were between 51 and
60 years with 4.9 % less than 40 years. The average age
of male and female patients was 56.9 ± 10 and 57.8 ± 7.
From the study sample 70.6 % (n = 72), 53.9 % (n = 55)
and 87.3 % (n = 89) individuals had a history of hyper-
tension, diabetes mellitus and dyslipidemia respectively.
Dyslipidemia was the most frequent disease related risk
factor among both males and females. Family history of
CHD was a risk among 54 % of the sample with females
having a higher frequency (77 %).
Lipid profile values (total cholesterol (TC), low density
lipoprotein cholesterol (LDLc), high density lipoprotein
cholesterol (HDLc), triglyceride (TG), TC:HDLc ratio),
and (Lp(a)) of the study sample are stated in Table 2.
The study sample consisted 87.3 % of patients on statins
which comprised 83.6 % of males and 94.3 % females.
The mean total cholesterol (<200 mg/dL) was well
within the normal reference. LDLc of some females
(36 %) on treatment were higher than recommended.
Females on statins (n = 33) had significantly high TC
(p = 0.001), LDLc (p = 0.02) and HDLc (p = 0.02) when
compared to males on statins. From among 50 patients on
statin therapy most patients (n = 48) were on atovastatin,
either 20 mg (60 %) or 40 mg. However, the exact dose
and the type of statin were not available for the other
patients (n = 39). The TC:HDLc ratio was above 4.5 in
majority of subjects.
Irrespective of statin therapy the Lp(a) concentration
was not significantly different among males or females
and was higher than 45 mg/dL. Variation of lipid profile
values with high and low Lp(a) concentrations is stated
in Table 3. The average TC and LDLc were within the nor-
mal range irrespective of Lp(a) being above 30 mg/dL
(upper limit reagent kit) or more than 25 mg/dL as
suggested cutoff for South Asians [12].
Discussion
The mean concentrations of TC, LDLc, TG of both males
and females on statin therapy and without statins were
within the recommended [23] concentrations with lower
HDLc. However, even though the therapeutic target of
LDLc is <100 mg/dL for a person with CHD, 26.7 %
(n = 27) from the total sample had higher LDLc con-
centrations and 8.8 % (n = 9) of females had TC concen-
tration >200 mg/dL indicating inadequate control despite
treatment. Haddad et al. [24] also reported mean values of
LDLc as 146.7 ± 50.9 mg/dL and 118.9 ± 45.9 mg/dL of
patients confirmed as CHD and that of controls respect-
ively. The prevalence of hypercholesterolemia and mean
total cholesterol concentration in Sri Lankan adults were
53.6 % and 5.35 ± 1.13 mmol/L (206.5 ± 43.6 mg/dL)
respectively [8]. According to non-fasting results of
total cholesterol, the prevalence of high TC was 20–
25.9 % [25]. These data are a clear indication of the
necessity in controlling not only total cholesterol but
also the LDLc.
Table 1 Demographic and risk factor data of the study sample
Variable Total Male (n = 67) Female (n = 35)
Age 57 ± 9 56.9 ± 10 57.8 ± 7
Residency Urban 59.8 % 55.2 % 68.6 %
Rural 40.2 % 44.8 % 31.4 %
Monthly income (LKR) <10 000 10.8 % 10.4 % 11.4 %
11 000–30 000 72.5 % 70.1 % 77.1 %
>31 000 16.7 % 19.4 % 11.5 %
Disease related risk factors
Hypertension Hypertensive 70.6 % 58.2 % 94.3 %
Normotensive 29.4 % 41.8 % 5.7 %
Diabetes Mellitus Diabetic 53.9 % 53.7 % 54.3 %
Non Diabetic 46.1 % 46.3 % 45.7 %
Dyslipidemia Dyslipidemic 87.3 % 83.6 % 94.3 %
Non dyslipidemic 12.7 % 16.4 % 5.7 %
Family history of CAD With family history 53.9 % 41 % 77 %
No family history 46.1 % 59 % 23 %
Severity of CAD Gensini score 48 ± 26 51 ± 25 44 ± 2
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When considering the TG, 30.4 % males and females
had triglyceride above 150 mg/dL. Correlating with
above the waist to hip ratio of more than 90 % of the
study sample indicated high risk [26]. HDLc concentra-
tions of 77.5 % of patients were less than 40 mg/dL. The
low HDLc correlated with the low physical activity level
and the high prevalence of central obesity [26] in the
present study sample. Majority of the patients [n = 89] in
this study were on statins and mean concentrations of
TC and LDLc were within the reference range [23].
However, since the exact dose and the statin are not
available for some (n = 39) we are unable to make any
inference on the dose and type correlations and lipid
parameters. Notably, 45 % among the study sample was
unaware that they were on statins and dyslipidemic
despite good compliance. Thus the consumption of red
meat, chicken, fish, egg with yolk and fast food was
comparatively higher in the group who were not aware
that they were dyslipidemic [26].
The above indicates that it is necessary to make the
patients aware regarding usage of drugs which may
reduce the adverse effects if any occur. Likewise, with
prescription of drugs, information on lifestyle changes to
maintain lipid parameters within normal ranges need to
be imparted to these patients as above data shows this
information is lacking.
TC:HDLc ratio of majority of patients was above 4.5.
It clearly indicates that even though cholesterol was
below the recommended value their HDLc need to be
increased. Lifestyle changes are now being advocated to
such patients. By and large a cut off of <5 for this ratio
is being used in most Sri Lankan hospitals and thus it is
necessary to evaluate the suitability of reducing the cut-
off given the susceptibility of South Asians to Acute
Myocardial Infarction (AMI) at an earlier age [2].
Lipoprotein(a) excess is an independent risk factor for
coronary artery disease [9]. Lipoprotein (a) concentration
of dyslipidemic (49.6 ± 38.5 mg/dL) and non dyslipidemic
(51.1 ± 39.6 mg/dL) patients were not significantly differ-
ent and 166 % higher than the cut-off (30 mg/dL) accord-
ing to the present study and confirms its potential as an
independent risk factor for CAD even among Sri Lankans.
Despite the fact that male gender is a risk factor for CAD
a non significant increase in Lp(a) in females was ob-
served. This could be due to the lower samples size when
compared to the males. A study where normolipidemic
acute myocardial infarct (AMI) patients and controls of
both Sri Lankan and Indian origin had been studied indi-
cated a significantly high (p = 0.0001) concentration of
Lp(a) [27] in the test group. This also clearly proves the
importance of Lp(a) as an independent and an early
marker for assessing the susceptibility for CAD especially
in those with other intermediate risk factors such as
hypertension, diabetes, overweight and obese with a family
history but considered non-hyperlipidemic by conven-
tional methods. However, around 2/3 of patients in this
study samples had Lp(a) concentration >30 mg/dL, which
is the upper limit of the reference suggested by the kit.





Total (n = 102) Male
(n = 67)
Male (n = 67) Female
(n = 35)
Female (n = 35)
A (n = 89) B (n = 13) A (n = 56) B (n = 11) A (n = 33) B (n = 2)
aTC (< 200) 150 ± 36 152 ± 36 137 ± 31 142 ± 29 143 ± 28 135 ± 33 167 ± 43# 168 ± 44* 151 ± 19
aLDLc (< 100) 92 ± 36 94 ± 37 82 ± 27 85 ± 24 87 ± 24 80 ± 28 105 ± 49# 105 ± 50* 98 ± 4.2
aHDLc (> 40) 34 ± 9 34 ± 10 31 ± 8 32 ± 9 32 ± 10 31 ± 8 37 ± 8# 37 ± 9* 33 ± 5.6
aTG (<150) 133 ± 60 134 ± 60 124 ± 64 127 ± 53 127 ± 51 129 ± 67 143 ± 71 146 ± 72 98 ± 45
cTC:HDL (< 5) 4.6 ± 1.2 4.6 ± 1.3 4.5 ± 1.0 4.6 ± 1.1 4.6 ± 1.2 4.5 ± 1.1 4.7 ± 1.4 4.6 ± 1.4 4.6 ± 0.2
bLp(a) (< 30) 50 ± 38 50 ± 39 49 ± 39 47 ± 37 47 ± 36 49 ± 40 54 ± 41 54 ± 42 56 ± 41
A; on statins, B; without statins, TC; total cholesterol, LDLc; low density lipoprotein cholesterol, HDLc; high density lipoprotein cholesterol, TG; triglyceride
#Significant differences (p < 0.05) between male and female total concentrations; *Significant difference (p < 0.05) between male and females on statins
aThird Report of the National Cholesterol Education Programme (Adult Treatment Panel III), 2002 (23)
bReference range as per lipoprotein(a) kit









TC (< 200 mg/dL) 154.6 ± 32.2 143.3 ± 39.6 153.7 ± 34.3 142.0 ± 39.2
LDLc (< 100 mg/dL) 95.4 ± 28.9 84.4 ± 33.5 94.3 ± 30.1 83.8 ± 32.6
HDLc (> 40 mg/dL) 34.3 ± 7.4 33.0 ± 11.9 34.7 ± 9.8 31.7 ± 8.0
TG (<150) 128.7 ± 47.0 138.5 ± 77.0 131.2 ± 48.4 135.9 ± 82.6
TC:HDLc (< 5) 4.6 ± 1.2 4.6 ± 1.4 4.6 ± 1.2 4.6 ± 1.3
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This percentage is further increased when considering the
cut-off value (>25 mg/dL) suggested for the South Indian
population [12]. Except one patient who had a Lp(a)
concentration of 1.3 mg/dL and was hyperlipidemic, all
others had Lp(a) concentration >10 mg/dL. Therefore, a
Lp(a) lower than 30 mg/dL is suggested as the cutoff to
determine susceptibility of Sri Lankans to CAD con-
sidering the reported ethnic variation in Lp(a) [20].
However, for this Lp(a) levels of a control group
needs to be studied.
Over 90 % of patients had TC within the recom-
mended level and most had LDLc also within the normal
range due to being on statin therapy. This indicates even
with normal TC and LDLc, Lp(a) would indicate the
CAD risk and can be considered as a potential inde-
pendent risk marker as all the patients enrolled in this
study were to undergo CABG.
High fat intake may lead to higher plasma Lp(a) levels
in patients [28]. This could be correlated to the >20 % of
expatriate workers both male and female who informed of
dietary pattern changes towards high fat intake while
living outside Sri Lanka. When their family history was
considered, 64 % with family history had Lp(a) >30 mg/
dL. This indicates that other factors such as diet may also
have contributed to the increase in Lp(a) and the develop-
ment of CAD in these patients.
Female sex, family history of CHD, high concentra-
tions of TC and LDLc were reported to be associated
with high concentration of Lp(a) [12]. In the present
study an association with female sex and Lp(a) was ob-
served. Europe and Atherosclerosis Society Consensus
Panel also recommends screening of Lp(a) in individuals
with intermediate or high risk of cardiovascular
diseases/CHD. Lp(a) concentration of <50 mg/dL was
suggested as a desirable level as a function of global
cardiovascular risk [29]. In the present sample 2/3 of
patients had Lp(a) of >30 mg/dL indicating a lower
cutoff for Sri Lankans can also be considered as Lp (a)
levels have shown wide ethnic variations [20] and are
susceptible to change with the dietary patterns [28].
Similarly a Lp(a) concentration of 25 mg/dL had been
suggested as the cutoff as risk of CHD in a South Indian
study [12]. It is also recommended Lp(a) to be consi-
dered an additional marker for screening for CAD in
susceptible individuals.
Limitations
Comparison of data on Lp(a) and lipid profiles with an
age and sex matched apparently healthy control group
would have improved the study outcome.
A complete data set on the type and the intensity of
statin therapy would have helped to find their effect on
lipid parameters and the severity of the disease.
Conclusions
Notwithstanding pharmacological interventions 27 % of
the study population had high LDLc with more among
females. Majority of patients had low HDLc and a
TC:HDLc ratio of <5 which is within the recommended
range. This highlights the urgent need for considering a
lower cut-off for Sri Lankan population as there is clear
evidence of increasing prevalence of CAD among Sri
Lankans according to reported data. Lp(a) could be
considered as an independent, potential marker for
assessing the susceptibility for CAD in Sri Lankans
especially in those with other intermediate risk factors
but considered non-hyperlipidemic by conventional
methods.
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